Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 2
2014 1
2017 1
2019 1
2020 1
2021 5
2022 3
2023 3
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
Multidrug-resistant tuberculosis.
Nyang'wa BT, Berry C, Fielding K, Nunn AJ. Nyang'wa BT, et al. Lancet. 2019 Jul 27;394(10195):298-299. doi: 10.1016/S0140-6736(19)30691-9. Lancet. 2019. PMID: 31354136 No abstract available.
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh TD, Merle C, Motta I, Moore DAJ, Nyang'wa BT. Berry C, et al. Among authors: nyang wa bt. Trials. 2022 Jun 13;23(1):484. doi: 10.1186/s13063-022-06331-8. Trials. 2022. PMID: 35698158 Free PMC article.
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, Rajaram S, Rassool M, McHugh T, Spigelman M, Moore DA, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL team. Nyang'wa BT, et al. Lancet Respir Med. 2024 Feb;12(2):117-128. doi: 10.1016/S2213-2600(23)00389-2. Epub 2023 Nov 16. Lancet Respir Med. 2024. PMID: 37980911 Free article. Clinical Trial.
Target regimen profiles for tuberculosis treatment.
Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, Kendall EA, Davies G, Brigden G, Churchyard G, Cirillo DM, Di Meco E, Gopinath R, Mitnick C, Scott C, Amanullah F, Bansbach C, Boeree M, Campbell M, Conradie F, Crook A, Daley CL, Dheda K, Diacon A, Gebhard A, Hanna D, Heinrich N, Hesseling A, Holtzman D, Jachym M, Kim P, Lange C, McKenna L, Meintjes G, Ndjeka N, Nhung NV, Nyang'wa BT, Paton NI, Rao R, Rich M, Savic R, Schoeman I, Makokotlela BS, Spigelman M, Sun E, Svensson E, Tisile P, Varaine F, Vernon A, Diul MY, Kasaeva T, Zignol M, Gegia M, Mirzayev F, Schumacher SG. Lienhardt C, et al. Among authors: nyang wa bt. Bull World Health Organ. 2024 Aug 1;102(8):600-607. doi: 10.2471/BLT.24.291881. Epub 2024 May 28. Bull World Health Organ. 2024. PMID: 39070602 Free PMC article.
The 1/4/6x24 campaign to cure tuberculosis quickly.
McKenna L, Frick M, Angami K, Dubula V, Furin J, Harrington M, Hausler H, Heitkamp P, Herrera R, Lynch S, Mitnick CD, Moses GK, Ndjeka N, Nyang'wa BT, Palazuelos L, Ulysse P, Pai M. McKenna L, et al. Among authors: nyang wa bt. Nat Med. 2023 Jan;29(1):16-17. doi: 10.1038/s41591-022-02136-z. Nat Med. 2023. PMID: 36627438 No abstract available.
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, Dodd M, Foraida S, Gegia M, Li M, Mirzayev F, Morgan H, Motta I, Nguyen L, Schumacher S, Schlub T, Fox G. Hasan T, et al. Among authors: nyang wa bt. Clin Infect Dis. 2024 Mar 20;78(3):730-741. doi: 10.1093/cid/ciad653. Clin Infect Dis. 2024. PMID: 37874021 Free PMC article. Review.
Standards for clinical trials for treating TB.
du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh KP, Motta I, Lange C, Seddon JA, Nyang'wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh CR, Dheda K, Marais BJ. du Cros P, et al. Among authors: nyang wa bt. Int J Tuberc Lung Dis. 2023 Dec 1;27(12):885-898. doi: 10.5588/ijtld.23.0341. Int J Tuberc Lung Dis. 2023. PMID: 38042969 Free PMC article.
Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL.
Crocker-Buque T, Lachenal N, Narasimooloo C, Abdrasuliev T, Parpieva N, Tigay Z, Liverko I, Usmanova R, Butabekov I, Moodliar R, Mbenga M, Rasool M, Nyang'wa BT, Berry C. Crocker-Buque T, et al. Among authors: nyang wa bt. Clin Infect Dis. 2024 Aug 16;79(2):569-570. doi: 10.1093/cid/ciad767. Clin Infect Dis. 2024. PMID: 38419566 Free PMC article. No abstract available.
23 results